Jazz Pharmaceuticals account plan
developing novel medicines globally
At a glance
Jazz Pharmaceuticals is a Dublin-based rare disease biopharma (sleep, epilepsy, oncology): $4,267.6 million 2025 revenue, about 2,890 employees.
Jazz Pharmaceuticals plc is a Dublin-headquartered biopharmaceutical company focused on rare disease, with marketed medicines in rare sleep disorders (Xywav, Xyrem), rare epilepsies (Epidiolex/Epidyolex) and rare cancers (Ziihera, Modeyso, Zepzelca, Rylaze, Vyxeos, Defitelio). It has direct commercial operations in the U.S., Europe, Australia and Canada and manufactures in Ireland, the U.K. and Italy; U.S. revenues were $3,831.6 million of the 2025 total. FY2025 total revenues were $4,267.6 million (+5%) with a net loss of $356.1 million, driven by acquired IPR&D and litigation settlements. It employed approximately 2,890 people at 31 December 2025, about 53% in the U.S.; Renee D. Gala is President and CEO.
Business units
Neuroscience: rare sleep (Xywav, Xyrem)
about 67% of 2025 total revenues ($2,878.5 million of product sales, computed)Xywav, the largest product at $1,657.0 million in 2025 (41% of net product sales), treats narcolepsy and is the only FDA-approved therapy for idiopathic hypersomnia in adults; Xyrem declined 38% on high-sodium generic competition. In Q3 2026 Xywav sales rose 12% to $482.8 million with about 17,550 active patients.
Neuroscience: rare epilepsy (Epidiolex/Epidyolex)
26% of 2025 net product sales ($1,059.2 million)Cannabidiol oral solution for seizures in Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, reimbursed in more than 40 countries. Q3 2026 sales slipped 2% to $295.4 million; a capsule formulation NDA has a PDUFA date of 16 April 2027 and the Actio acquisition added ABS-1230 for KCNT1-related epilepsy.
Oncology
about 26% of 2025 total revenues ($1,129.2 million of product sales, computed)Rylaze, Zepzelca, Defitelio, Vyxeos, Modeyso and Ziihera, sold to hospitals and oncology clinics. Q3 2026 oncology sales were $387.1 million (Q3 2025: $287.8 million), with Zepzelca up 32% and Ziihera approved in first-line HER2-positive GEA on 25 August 2026.
Strategic priorities
- Ziihera launch in first-line GEA
- FDA approval on 25 August 2026 in first-line HER2-positive GEA, targeting 3,000 to 4,000 U.S. patients a year; Jazz puts Ziihera's peak sales potential at $3 billion to $5 billion.
- Revenue diversification away from oxybates
- Xyrem plus high-sodium oxybate AG royalty revenue fell from 74% of total revenue in 2020 to 8% in 2025, with growth now driven by Modeyso, Ziihera and Epidiolex.
- Rare disease business development
- Jazz looks at licensing, structured deals and outright M&A in rare disease; it acquired Chimerix in 2025 and Actio for $820 million in 2026.
- Defending Xywav
- Management expects Xywav to remain foundational across NT1, NT2 and idiopathic hypersomnia, backed by Orange Book-listed patents to 2033 and 2037 and an IH patent to 2041.
- Advancing the late-stage pipeline
- Phase 3 trials for zanidatamab in breast cancer (EmpowHER-BC-303) and dordaviprone in diffuse glioma (ACTION, readout expected in 1H27), plus Jazz's own orexin 2 receptor agonist JZP269.
Latest results
In Q3 2026 Jazz reported record total revenues of $1,243.0 million, up 10% from $1,126.1 million, and $3,520.2 million for nine months. Xywav grew 12% and oncology sales reached $387.1 million, while Epidiolex/Epidyolex slipped 2%. The GAAP net loss was $483.4 million after $754.2 million of acquired IPR&D from the Actio acquisition. Full-year 2026 total revenue guidance was raised to $4,775-4,850 million from $4,600-4,750 million in August, nearly 13% growth at the midpoint.
Investments and deals
- Actio acquisition
- Closed in September 2026 for $820 million, adding ABS-1230 (JZP6979), a potential first-in-class therapy for KCNT1-related epilepsy.
- Chimerix acquisition
- Acquired in 2025 for $944.2 million, bringing Modeyso, which reached about $200 million of sales and 725 patients since its August 2025 launch.
- Saniona licence
- JZP053 (Kv7.2/Kv7.3 activator) licensed in August 2025 for $42.5 million upfront.
- Financing and buybacks
- A $1.25 billion private placement of 1.875% exchangeable notes due 2032, $225 million of share repurchases, a new $500 million programme approved in October 2026, and the Term Loan B extended to May 2033.
Challenges and risks
- Oxybate competition
- Lumryz, authorized generics, approved high-sodium generics, Xywav ANDA filers and orexin 2 receptor agonists in development at several companies threaten the sleep franchise.
- Drug pricing reform
- IRA Medicare negotiation, Medicaid rebate changes and CMS most-favoured-nation models, plus uncertainty on MFN pricing for Ziihera outside the U.S.
- Tariffs on manufacturing
- Tariffs on pharmaceutical imports could hit margins as early as fiscal 2026 given manufacturing in Ireland, the U.K. and Italy; Jazz increased U.S. inventory in anticipation.
- Debt load
- Long-term debt principal was $5.6 billion at 30 September 2026 against $2.9 billion of cash, cash equivalents and investments.
- Oncology competition
- Amgen's IMDELLTRA is expected to be a headwind for Zepzelca in 2027, and Modeyso faces a more measured revenue pace in the near term.
What leadership says
“was a defining milestone for Jazz, establishing an important new source of growth”
“As we enter 2027, we have clear priorities, the financial strength to invest behind them and a strong track record of execution.”
“We are highly engaged on the BD front, and I do expect us to have deals announced over the course of this year.”
Where a supplier can help
- Community oncology launch support
- Tied to the Ziihera launch: the commercial strategy broadens reach to community accounts, where about 80% of new ordering accounts sit, so field enablement, HCP engagement and data services are relevant.
- Clinical trial services
- Tied to the late-stage pipeline: CRO, site and data services fit Phase 3 trials such as EmpowHER-BC-303 and ACTION and the registrational KYRON trial.
- Supply chain resilience
- Tied to the tariff challenge: manufacturing, inventory and trade-compliance offers address a stated margin risk on Irish, U.K. and Italian production.
- Patient support programmes
- Tied to defending Xywav: management credits JazzCares support services and the REMS for limiting generic erosion, so patient services and adherence tools fit.
- Business development diligence
- Tied to rare disease business development: advisory, diligence and integration support match an active deal strategy after Chimerix and Actio.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Jazz Pharmaceuticals?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for the fiscal year ended December 31, 2025
- Jazz Pharmaceuticals plc is a Dublin-headquartered global biopharmaceutical company focused on rare disease, with leading therapies in epilepsies, cancers and sleep disorders; it reports one operating segment and derives most revenue from the U.S.
- FY2025 total revenues were $4,267.6 million (+5%), of which product sales, net $4,021.8 million; U.S. revenues were $3,831.6 million, Europe $341.1 million, all other $94.9 million.
- Xywav is the largest product: $1,657.0 million of net product sales (41% of total net product sales), about 16,175 patients at end-2025 (10,950 narcolepsy, 5,225 idiopathic hypersomnia); Epidiolex/Epidyolex added $1,059.2 million (26%).
- The rare oncology portfolio (Rylaze, Zepzelca, Defitelio, Vyxeos, Modeyso, Ziihera) totalled $1,129.2 million (+2%); Modeyso, approved August 2025 after the $944.2 million Chimerix Acquisition, sold $48.0 million in its launch year.
- Diversification away from Xyrem: in 2020, 74% of total revenue came from Xyrem; in 2025 Xyrem plus high-sodium oxybate AG royalty revenue was 8% of total revenue.
- The company posted a net loss of $356.1 million in 2025, driven by $947.9 million of acquired IPR&D (Modeyso and the Saniona licence) and $323.5 million of litigation settlements (Xyrem antitrust and Avadel).
- Balance sheet at 31 December 2025: $2.4 billion of cash, cash equivalents and investments, $5.4 billion of long-term debt principal, $885.0 million undrawn revolver; operating cash flow $1.4 billion.
- Pipeline priorities: zanidatamab (Ziihera) in first-line HER2-positive GEA after positive Phase 3 HERIZON-GEA-01 results, plus breast cancer and BTC trials; the Phase 3 ACTION trial for dordaviprone; early epilepsy and neuroscience assets.
- Key risks: oxybate competition (Lumryz, authorized generics, approved high-sodium generics, Xywav ANDA filers, orexin 2 receptor agonists in development), drug pricing reform (IRA, MFN models), and tariffs on its Irish, U.K. and Italian manufacturing.
- About 2,890 employees at end-2025, 53% in the U.S.; more than 740 support R&D. CEO Renee D. Gala, CFO Philip L. Johnson.
- Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results (8-K Exhibit 99.1)
- Q3 2026 (quarter to 30 September) total revenues reached a record $1,243.0 million, +10% YoY; nine-month revenues $3,520.2 million.
- Full-year 2026 total revenue guidance raised to $4,775-4,850 million (from $4,600-4,750 million in August).
- Xywav net product sales rose 12% to $482.8 million, with about 425 net patient adds and about 17,550 active patients (11,375 narcolepsy, 6,175 idiopathic hypersomnia).
- Oncology sales were $387.1 million (Q3 2025: $287.8 million): Zepzelca +32% to $104.4 million on first-line maintenance uptake, Modeyso $61.1 million, Ziihera $20.6 million after FDA approval in first-line HER2+ GEA on 25 August 2026.
- Epidiolex/Epidyolex slipped 2% to $295.4 million on prior-year gross-to-net and inventory effects; a capsule formulation NDA has a PDUFA date of 16 April 2027.
- GAAP net loss of $483.4 million for the quarter after $754.2 million of acquired IPR&D for ABS-1230 (JZP6979) from the Actio acquisition; $34 million of restructuring expenses.
- Financing: $1.25 billion 1.875% exchangeable notes due 2032, $225 million of share buybacks, a new $500 million repurchase programme and a Term Loan B extended to May 2033.
- Cash, equivalents and investments of $2.9 billion against $5.6 billion of long-term debt principal; $1.3 billion cash from operations in nine months.
- Jazz (JAZZ) Q3 2026 Earnings Call Transcript
- CEO Renee Gala called the FDA approval and launch of Ziihera in first-line HER2-positive metastatic GEA "a defining milestone for Jazz"; peak sales potential for Ziihera is put at $3 billion to $5 billion.
- Record Q3 2026 revenue of $1.24 billion (+10%): oncology +35%, Xywav +12%; 2026 revenue guidance raised for the second quarter in a row to $4.775-4.85 billion, nearly 13% growth at the midpoint.
- Ziihera launch: target population of 3,000 to 4,000 U.S. patients a year; threefold rise in new ordering accounts in September, about 80% community clinics; 40% month-over-month rise in vial demand per selling day.
- Xywav: 17,550 active patients; high-sodium generics have had little impact; orexin 2 agonists may delay some new NT1 patients, but management sees Xywav as foundational in NT1, NT2 and IH.
- Modeyso: about $200 million of sales and 725 patients since launch; a "more measured revenue pace" in the near term as the launch moves into community oncology; $500 million U.S. peak expectation reaffirmed.
- Zepzelca grew 32% in first-line maintenance, but Amgen's IMDELLTRA is expected to be a headwind in 2027.
- Business development: Actio ($820 million) adds ABS-1230 for KCNT1 epilepsy; Gala wants more deals like Chimerix and Actio in rare disease.
- Chief Commercial Officer Samantha Pearce is retiring and will stay until a successor is appointed.
- Jazz (JAZZ) Q1 2026 Earnings Call Transcript
- Q1 2026 brought the highest-ever first-quarter revenue, more than 19% growth to $1.07 billion, with double-digit growth across all promoted brands; non-GAAP adjusted EPS was $6.34 and operating cash flow $408 million.
- Xywav sales rose 18% to $408 million with about 425 net patient adds (about 16,600 patients); Epidiolex grew 15% to $250 million on 16% volume growth.
- Zepzelca rose 60% to $101 million on first-line maintenance uptake; Modeyso sold $41 million with about 500 patients treated since launch, supporting a $500 million U.S. peak.
- CEO Renee Gala expected Ziihera to become "the HER2-targeted therapy of choice" in first-line HER2-positive GEA (PDUFA 25 August 2026).
- 2026 revenue guidance was reaffirmed at $4.25-4.5 billion, assuming second-half competition in sleep from high-sodium generics and wake-promoting agents.
- Gala: "I do expect us to have deals announced over the course of this year"; Jazz is looking at licensing, structured deals and outright M&A in rare disease, with $2.9 billion of cash and investments.
- Defending Xywav: Orange Book-listed patents to 2033 and 2037 and an IH patent to 2041; R&D chief Robert Iannone sees orexins as complementary to Xywav.
- Zepzelca patents extend to 2040; suits against five ANDA filers impose a stay of up to 30 months.
Questions about Jazz Pharmaceuticals
What does Jazz Pharmaceuticals do?
Jazz develops and sells medicines for rare diseases in sleep disorders, epilepsy and oncology, including Xywav, Epidiolex, Ziihera and Modeyso.
What was Jazz Pharmaceuticals' revenue in 2025?
Total revenues were $4,267.6 million in 2025, up 5%; 2026 guidance is $4,775-4,850 million.
How many employees does Jazz Pharmaceuticals have?
Approximately 2,890 at 31 December 2025, about 53% in the U.S.; more than 740 support R&D.
Who leads Jazz Pharmaceuticals?
Renee D. Gala is President and CEO and Philip L. Johnson is CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)